Successful treatment of ulcerated infantile hemangioma with brimonidine-timolol cream: 2 cases report and review of the literature

Ulceration is the most common complication of infantile hemangioma (IH). We reported two cases of ulcerated IH treated by new cream formulation of brimonidine 0.2%–timolol 0.5% (a combination of selective α-2-adrenergic agonist and nonselective β-blocker). In both cases, ulcerations were healed with...

Full description

Bibliographic Details
Main Author: Mishal Almebayadh
Format: Article
Language:English
Published: Taylor & Francis Group 2020-05-01
Series:Journal of Dermatological Treatment
Subjects:
Online Access:http://dx.doi.org/10.1080/09546634.2019.1603991
Description
Summary:Ulceration is the most common complication of infantile hemangioma (IH). We reported two cases of ulcerated IH treated by new cream formulation of brimonidine 0.2%–timolol 0.5% (a combination of selective α-2-adrenergic agonist and nonselective β-blocker). In both cases, ulcerations were healed within 7–10 days after twice-daily application. No topical or systemic side effects were reported. In conclusion, brimonidine 0.2%-timolol 0.5% cream is a promising alternative in the topical treatment of ulcerated hemangiomas.
ISSN:0954-6634
1471-1753